Sézary Syndrome and Dupixent Lawsuits
Diagnosed With Sézary Syndrome After Taking Dupixent?
Sézary syndrome is an aggressive form of cutaneous T-cell lymphoma that affects the skin, lymph nodes, and blood. Lawsuits allege that the makers of Dupixent failed to warn patients and doctors about a possible link between the drug and T-cell lymphoma. If you used Dupixent and were later diagnosed with Sézary syndrome, you may be eligible to file a claim.
- No fee unless you recover
- 100% confidential
- Nationwide claims
- Consolidated in federal court
What Is Sézary Syndrome?
Sézary syndrome is an aggressive, advanced form of cutaneous T-cell lymphoma. It is defined by a combination of features: widespread red, scaling skin that can cover most of the body, a condition called erythroderma, along with enlarged lymph nodes and cancerous T-cells, known as Sézary cells, circulating in the bloodstream.
Because it involves the blood and not only the skin, Sézary syndrome is considered more serious than early-stage mycosis fungoides and typically requires intensive treatment. Some patients are diagnosed with Sézary syndrome directly, while in others it develops after a prior cutaneous T-cell lymphoma. The widespread skin involvement can, like other forms of CTCL, be confused at first with severe eczema or other inflammatory skin conditions.
How Sézary Syndrome Fits the Litigation
The Dupixent lawsuits cover cutaneous T-cell lymphoma broadly, and Sézary syndrome is one of the most serious diagnoses within that group. Plaintiffs allege that Dupixent may trigger or accelerate T-cell lymphoma in some patients, and that in others it may have suppressed visible skin symptoms while the underlying disease advanced, delaying diagnosis.
Studies have reported elevated rates of cutaneous T-cell lymphoma among patients treated with Dupixent. As of June 2026, the drug's FDA-approved label does not carry a specific warning about CTCL or lymphoma, even though the FDA has flagged CTCL as a potential safety signal connected to the medication. Because Sézary syndrome is advanced and aggressive, the stakes for patients and their families are significant, and a delayed diagnosis can matter a great deal.
Signs and Symptoms Patients Report
- Widespread red, itchy, scaling skin covering large areas of the body
- Intense itching that interferes with sleep and daily life
- Thickened skin on the palms and soles
- Hair loss
- Changes to the nails
- Enlarged lymph nodes
- Fatigue and other symptoms related to blood involvement
Where the Cases Stand
On June 4, 2026, federal Dupixent T-cell lymphoma cases were consolidated into MDL No. 3180 in the U.S. District Court for the District of New Jersey before Judge Zahid N. Quraishi. The defendants are Regeneron Pharmaceuticals and Sanofi-Aventis U.S. The litigation is in its early stages. No settlements have been reached, and no outcome is guaranteed. Given the seriousness of a Sézary syndrome diagnosis and state filing deadlines, a prompt review is worthwhile.
Current as of June 2026. The litigation is active and ongoing. No settlements have been reached, and no outcome is guaranteed.
Ready to find out if you have a claim?
Take a few minutes to share your story. There is no cost and no obligation, and your information stays confidential.
Or call 800-280-0420